PS www.ProStocks.com
|
|
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.
Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.
As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
| IPO Date | Apr 25, 2023 to Apr 27, 2023 |
| Listing Date | May 9, 2023 |
| Face Value | ₹1 per share |
| Price | ₹1026 to ₹1080 per share |
| Lot Size | 13 Shares |
| Total Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹4,326.36 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | 8,011,769 (20.00%) |
| NII (HNI) Shares Offered | 6,008,827 (15.00%) |
| Retail Shares Offered | 14,020,596 (35.00%) |
| Anchor Investor Shares Offered | 12,017,652 (30.00%) |
| Total Shares Offered | 28,041,192 |
| Total Shares With Anchor Investor | 40,058,844 |
Mankind Pharma IPO Anchor Investors list
| Bid Date | Apr 24, 2023 |
| Shares Offered | 12,017,652 |
| Anchor Portion Size (In Cr.) | 1,297.91 |
| Anchor lock-in period end date for 50% shares (30 Days) | Jun 14, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sep 8, 2023 |
Mankind Pharma IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.
| Event | Tentative Date |
|---|---|
| Opening Date | Tuesday, 25 April 2023 |
| Closing Date | Thursday, 27 April 2023 |
| Basis of Allotment | Wednesday, 3 May 2023 |
| Initiation of Refunds | Thursday, 4 May 2023 |
| Credit of Shares to Demat | Friday, 5 May 2023 |
| Listing Date | Tuesday, 9 May 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on Apr 27, 2023 |
The Mankind Pharma IPO lot size is 13 shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹196,560 |
| S-HNI (Min) | 15 | 195 | ₹210,600 |
| S-HNI (Max) | 71 | 923 | ₹996,840 |
| B-HNI (Min) | 72 | 936 | ₹1,010,880 |
| Lot Size Calculator | |||
Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust are the company promoters.
| Pre Issue Share Holding | 79.00% |
| Post Issue Share Holding | 76.50% |
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 | 3,485.31 | 3,436.34 | 126.92 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 | 4,722.00 | 4,674.39 | 234.53 |
| 31-Dec-21 | 8,043.88 | 6,218.29 | 1,260.24 | 5,965.46 | 5,916.86 | 268.70 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 | 6,155.23 | 6,106.06 | 868.03 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 | 7,145.89 | 7,094.12 | 167.93 |
| Amount in ₹ Crore | ||||||
| KPI | Values |
|---|---|
| P/E (x) | 32.5 |
| Market Cap (₹ Cr.) | 43263.6 |
| ROE | 27.6 |
| ROCE | 26.1 |
| EPS (Rs) | 33.2 |
| RoNW (%) | 27.7 |
The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer.
[Dilip Davda] A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective. Read detail review...
The Mankind Pharma IPO is subscribed 15.32 times on Apr 27, 2023 7:02:00 PM. The public issue subscribed 0.92 times in the retail category, 49.16 times in the QIB category, and 3.80 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 49.16 |
| NII | 3.80 |
| bNII (bids above ₹10L) | 4.99 |
| sNII (bids below ₹10L) | 1.41 |
| Retail | 0.92 |
| Total | 15.32 |
Total Application : 462,789 (0.43 times)
| Listing Date | May 9, 2023 |
| BSE Script Code | 543904 |
| NSE Symbol | MANKIND |
| ISIN | INE634S01028 |
| Final Issue Price | ₹1080 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,424.05 |
| NSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,080.00 |
Mankind Pharma Limited
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
Phone: +91 11 4684 6700
Email: investors@mankindpharma.com
Website: https://www.mankindpharma.com/
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: mankind.ipo@kfintech.com
Website: https://karisma.kfintech.com/
Mankind Pharma IPO is a main-board IPO of 40,058,844 equity shares of the face value of ₹1 aggregating up to ₹4,326.36 Crores. The issue is priced at ₹1026 to ₹1080 per share. The minimum order quantity is 13 Shares.
The IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.
Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Mankind Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Mankind Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Mankind Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Mankind Pharma IPO opens on Apr 25, 2023 and closes on Apr 27, 2023.
Mankind Pharma IPO lot size is 13 Shares and the minimum order quantity is .
You can apply in Mankind Pharma IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Mankind Pharma IPO will be done on Wednesday, 3 May 2023, and the allotted shares will be credited to your demat account by Friday, 5 May 2023. Check the Mankind Pharma IPO allotment status.
Top Contributor (400+ Posts, 200+ Likes)
Top Contributor (300+ Posts, 100+ Likes)
Useful Articles
FREE Account Opening (₹0)
FREE Intraday Trading (Eq, F&O)
30 days brokerage free trading
Free - Relationship Manager
Free - Classroom Training
|
|
RHP
IPO Mentor (900+ Posts, 300+ Likes)
New Member
IPO Guru (1100+ Posts, 600+ Likes)
